Noradrenergic regulation

Norepinephrine signalling is regulated across central and peripheral tissues through synthesis, release, reuptake, metabolism, receptor signalling, and feedback. This review describes the public biology relevant to AVX-1 and the limits of what can be inferred from it.

This review is classified as preclinical evidence and was last reviewed August 21, 2026.

A distributed regulatory system

Evidence context. Preclinical evidence.

Norepinephrine participates in arousal, autonomic regulation, attention, stress-related responses, and other functions across central and peripheral tissues. Locus coeruleus projections are broad but not necessarily homogeneous.

Distribution matters because the same molecular target may participate in different functions across tissues, projection-defined circuits, levels of endogenous signalling, and physiological states. Target identity alone therefore cannot predict the full consequence of an intervention.

Feedback and physiological state

Evidence context. Aeviant interpretation.

Norepinephrine signalling is regulated through synthesis, release, reuptake, metabolism, receptor signalling, and autoreceptor-mediated feedback. These controls operate as an interacting system.

Aeviant interprets this regulatory structure as a reason to test activity-dependent pharmacology: where a mechanism supports it, drug activity may be able to retain some dependence on the body’s own signal alongside drug exposure. Direct pharmacological tests will determine whether that state dependence occurs.

From biology to program evidence

Evidence context. Requires validation.

Circuit and receptor biology can identify a research question. A viable drug candidate, therapeutic window, neuroprotective effect and human benefit each require their own evidence.

Limitations

Much of the mechanistic evidence comes from rodents, brain slices, electrophysiology, optogenetic perturbation, and selected nonhuman-primate recordings. It does not establish a therapeutic mechanism, human translation, or any experimental property of AVX-1.

Relevance to the current program

AVX-1 asks whether the α2A-adrenergic autoreceptor can be modulated in a way that retains dependence on endogenous norepinephrine. This Aeviant interpretation defines a question for experimental testing.

Evidence records

The Evidence Library contains the source, relevance and limitations for each record used in this review.

Further reading: The α2A-adrenergic autoreceptor, the evidence library, and AVX-1.